Kevin Bitterman Sells 68,923 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 68,923 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $91.24, for a total transaction of $6,288,534.52. Following the transaction, the director directly owned 14,161 shares of the company’s stock, valued at $1,292,049.64. The trade was a 82.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Kevin Bitterman also recently made the following trade(s):

• On Friday, December 12th, Kevin Bitterman sold 45,507 shares of Disc Medicine stock. The stock was sold at an average price of $92.39, for a total value of $4,204,391.73.
• On Monday, December 15th, Kevin Bitterman sold 62,693 shares of Disc Medicine stock. The stock was sold at an average price of $91.28, for a total value of $5,722,617.04.
• On Monday, December 15th, Kevin Bitterman sold 7,000 shares of Disc Medicine stock. The shares were sold at an average price of $91.87, for a total value of $643,090.00.
• On Friday, October 17th, Kevin Bitterman sold 70,000 shares of Disc Medicine stock. The shares were sold at an average price of $88.91, for a total value of $6,223,700.00.
• On Thursday, October 16th, Kevin Bitterman sold 1,425 shares of Disc Medicine stock. The stock was sold at an average price of $77.11, for a total value of $109,881.75.
• On Wednesday, October 15th, Kevin Bitterman sold 22,160 shares of Disc Medicine stock. The shares were sold at an average price of $77.23, for a total value of $1,711,416.80.
• On Wednesday, October 8th, Kevin Bitterman sold 71,961 shares of Disc Medicine stock. The shares were sold at an average price of $70.58, for a total transaction of $5,079,007.38.
• On Tuesday, October 7th, Kevin Bitterman sold 18,039 shares of Disc Medicine stock. The stock was sold at an average price of $68.38, for a total transaction of $1,233,506.82.

Disc Medicine Stock Down 4.5%

Shares of NASDAQ IRON opened at $87.35 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The company’s 50 day moving average price is $87.33 and its 200-day moving average price is $68.35. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $99.50. The company has a market capitalization of $3.30 billion, a P/E ratio of -16.33 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Equities analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Disc Medicine by 22.2% during the 1st quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company’s stock valued at $64,782,000 after purchasing an additional 236,800 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Disc Medicine by 18.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 194,725 shares of the company’s stock valued at $9,666,000 after purchasing an additional 29,653 shares in the last quarter. Swiss National Bank boosted its position in shares of Disc Medicine by 11.5% during the first quarter. Swiss National Bank now owns 35,900 shares of the company’s stock valued at $1,782,000 after buying an additional 3,700 shares during the last quarter. Invesco Ltd. grew its holdings in Disc Medicine by 27.1% during the first quarter. Invesco Ltd. now owns 13,834 shares of the company’s stock worth $687,000 after buying an additional 2,953 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Disc Medicine in the 1st quarter valued at $5,595,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on IRON shares. Raymond James Financial restated a “strong-buy” rating and issued a $117.00 price target on shares of Disc Medicine in a report on Monday, December 8th. Truist Financial increased their price objective on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Wedbush upped their price target on Disc Medicine from $90.00 to $110.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Finally, Morgan Stanley increased their price target on Disc Medicine from $90.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $119.00.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.